MRI-based radiomics and ADC values are related to recurrence of endometrial carcinoma: a preliminary analysis

BMC Cancer

Table 1 Clinicopathological characteristics of recurrent and non-recurrent endometrial carcinoma in training and test group

Characteristics	Training group (n = 104)		P value	Test group (n = 70)		P value	P value
Characteristics	No recurrence (n = 88)	Recurrence (n = 16)	P value	No recurrence (n = 59)	Recurrence (n = 11)	P value	P value
Age at diagnosis (yr)	55.0 ± 9.2	59.6 ± 13.7	0.035	56.6 ± 7.2	60.9 ± 7.9	0.280	0.154
FIGO stage			< 0.001			0.006	0.026
IA	44(50.0%)	4(25.0%)		44(74.6%)	5(45.4%)
IB	12(13.6%)	2(12.5%)		3(5.1%)	2(18.2%)
II	18(20.5%)	1(6.2%)		11(18.6%)	1(9.1%)
IIIA	4(4.5%)	3(18.8%)		0(0.0%)	1(9.1%)
IIIC1	7(8.0%)	2(12.5%)		0(0.0%)	1(9.1%)
IIIC2	3(3.4%)	1(6.2%)		1(1.7%)	1(9.1%)
IVA	0(0.0%)	3(18.8%)		0(0.0%)	0(0.0%)
Tumor size (cm)			0.035			0.750	0.442
< 3.5	42(47.7%)	5(31.3%)		31(52.5%)	5(45.5%)
≥3.5	46(52.3%)	11(68.7%)		28(47.5%)	6(54.5%)
Pathological types			0.078			< 0.001	0.454
Endometrioid carcinoma	74(84.1%)	10(62.5%)		50(84.7%)	3(27.3%)
Non-endometrioid carcinoma	14(15.9%)	6(37.5%)		9(15.3%)	8(72.7%)
Myometrial invasion			0.001			0.135	0.730
< 50%	68(77.3%)	6(37.5%)		46(78.0%)	6(54.5%)
≥50%	20(22.7%)	10((62.5%)		13(22.0%)	5(45.5%)
LVSI			0.001			0.143	0.305
Absent	76(86.4%)	8(50.0%)		53(89.8%)	8(72.7%)
Present	12(13.6%)	8(50.0%)		6(10.2%)	3(27.3%)
LNM			0.410			0.062	0.106
Absent	78(88.6%)	13(81.3%)		58(98.3%)	9(81.8%)
Present	10(11.4%)	3(18.7%)		1(1.7%)	2(18.2%)
Ki-67			1.00			0.515	0.878
< 50%	44(50.0%)	8(50.0%)		30(50.9%)	4(36.4%)
≥50%	44(50.0%)	8(50.0%)		29(49.1%)	7(63.6%)

ISSN: 1471-2407